3
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Group Testing for SARS-CoV-2 Allows for Up to 10-Fold Efficiency Increase Across Realistic Scenarios and Testing Strategies

      methods-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background: Due to the ongoing COVID-19 pandemic, demand for diagnostic testing has increased drastically, resulting in shortages of necessary materials to conduct the tests and overwhelming the capacity of testing laboratories. The supply scarcity and capacity limits affect test administration: priority must be given to hospitalized patients and symptomatic individuals, which can prevent the identification of asymptomatic and presymptomatic individuals and hence effective tracking and tracing policies. We describe optimized group testing strategies applicable to SARS-CoV-2 tests in scenarios tailored to the current COVID-19 pandemic and assess significant gains compared to individual testing.

          Methods: We account for biochemically realistic scenarios in the context of dilution effects on SARS-CoV-2 samples and consider evidence on specificity and sensitivity of PCR-based tests for the novel coronavirus. Because of the current uncertainty and the temporal and spatial changes in the prevalence regime, we provide analysis for several realistic scenarios and propose fast and reliable strategies for massive testing procedures.

          Key Findings: We find significant efficiency gaps between different group testing strategies in realistic scenarios for SARS-CoV-2 testing, highlighting the need for an informed decision of the pooling protocol depending on estimated prevalence, target specificity, and high- vs. low-risk population. For example, using one of the presented methods, all 1.47 million inhabitants of Munich, Germany, could be tested using only around 141 thousand tests if the infection rate is below 0.4% is assumed. Using 1 million tests, the 6.69 million inhabitants from the city of Rio de Janeiro, Brazil, could be tested as long as the infection rate does not exceed 1%. Moreover, we provide an interactive web application, available at www.grouptexting.com, for visualizing the different strategies and designing pooling schemes according to specific prevalence scenarios and test configurations.

          Interpretation: Altogether, this work may help provide a basis for an efficient upscaling of current testing procedures, which takes the population heterogeneity into account and is fine-grained towards the desired study populations, e.g., mild/asymptomatic individuals vs. symptomatic ones but also mixtures thereof.

          Funding: German Science Foundation (DFG), German Federal Ministry of Education and Research (BMBF), Chan Zuckerberg Initiative DAF, and Austrian Science Fund (FWF).

          Related collections

          Most cited references72

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

          Background The ongoing outbreak of the recently emerged novel coronavirus (2019-nCoV) poses a challenge for public health laboratories as virus isolates are unavailable while there is growing evidence that the outbreak is more widespread than initially thought, and international spread through travellers does already occur. Aim We aimed to develop and deploy robust diagnostic methodology for use in public health laboratory settings without having virus material available. Methods Here we present a validated diagnostic workflow for 2019-nCoV, its design relying on close genetic relatedness of 2019-nCoV with SARS coronavirus, making use of synthetic nucleic acid technology. Results The workflow reliably detects 2019-nCoV, and further discriminates 2019-nCoV from SARS-CoV. Through coordination between academic and public laboratories, we confirmed assay exclusivity based on 297 original clinical specimens containing a full spectrum of human respiratory viruses. Control material is made available through European Virus Archive – Global (EVAg), a European Union infrastructure project. Conclusion The present study demonstrates the enormous response capacity achieved through coordination of academic and public laboratories in national and European research networks.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            A Mathematical Theory of Communication

            C. Shannon (1948)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia

              Abstract Background A novel coronavirus of zoonotic origin (2019-nCoV) has recently been identified in patients with acute respiratory disease. This virus is genetically similar to SARS coronavirus and bat SARS-like coronaviruses. The outbreak was initially detected in Wuhan, a major city of China, but has subsequently been detected in other provinces of China. Travel-associated cases have also been reported in a few other countries. Outbreaks in health care workers indicate human-to-human transmission. Molecular tests for rapid detection of this virus are urgently needed for early identification of infected patients. Methods We developed two 1-step quantitative real-time reverse-transcription PCR assays to detect two different regions (ORF1b and N) of the viral genome. The primer and probe sets were designed to react with this novel coronavirus and its closely related viruses, such as SARS coronavirus. These assays were evaluated using a panel of positive and negative controls. In addition, respiratory specimens from two 2019-nCoV-infected patients were tested. Results Using RNA extracted from cells infected by SARS coronavirus as a positive control, these assays were shown to have a dynamic range of at least seven orders of magnitude (2x10−4-2000 TCID50/reaction). Using DNA plasmids as positive standards, the detection limits of these assays were found to be below 10 copies per reaction. All negative control samples were negative in the assays. Samples from two 2019-nCoV-infected patients were positive in the tests. Conclusions The established assays can achieve a rapid detection of 2019n-CoV in human samples, thereby allowing early identification of patients.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Public Health
                Front Public Health
                Front. Public Health
                Frontiers in Public Health
                Frontiers Media S.A.
                2296-2565
                18 August 2021
                2021
                18 August 2021
                : 9
                : 583377
                Affiliations
                [1] 1Department of Mathematics, Technical University of Munich , Garching, Germany
                [2] 2Department of Electrical and Computer Engineering, Technical University of Munich , Munich, Germany
                [3] 3Research Network Data Science, University of Vienna , Vienna, Austria
                [4] 4Department of Telecommunications, Brno University of Technology , Brno, Czechia
                [5] 5Faculty of Mathematics, University of Vienna , Vienna, Austria
                [6] 6Institute of Computational Biology, Helmholtz Zentrum München , Munich, Germany
                [7] 7Johann Radon Institute for Computational and Applied Mathematics, Austrian Academy of Sciences , Linz, Austria
                [8] 8Munich Data Science Institute, Technical University of Munich , Garching, Germany
                Author notes

                Edited by: Olivier Vandenberg, Laboratoire Hospitalier Universitaire de Bruxelles (LHUB-ULB), Belgium

                Reviewed by: Elizaveta Padalko, Ghent University Hospital, Belgium; Mohamed Gomaa Kamel, Minia University, Egypt

                *Correspondence: Felix Krahmer felix.krahmer@ 123456tum.de

                This article was submitted to Infectious Diseases – Surveillance, Prevention and Treatment, a section of the journal Frontiers in Public Health

                †These authors have contributed equally to this work

                ‡These authors have contributed equally to the repository and the web application

                Article
                10.3389/fpubh.2021.583377
                8416485
                34490172
                58a82be7-aab6-43ef-af7c-a76757f78182
                Copyright © 2021 Verdun, Fuchs, Harar, Elbrächter, Fischer, Berner, Grohs, Theis and Krahmer.

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 14 July 2020
                : 26 July 2021
                Page count
                Figures: 6, Tables: 0, Equations: 6, References: 74, Pages: 13, Words: 11488
                Funding
                Funded by: Deutsche Forschungsgemeinschaft 10.13039/501100001659
                Award ID: BO 1734/20-1
                Award ID: GSC 1006
                Award ID: KR 4512/1-1
                Award ID: KR 4512/2-2
                Award ID: PO-1347/3-2
                Funded by: Bundesministerium f�r Bildung und Forschung 10.13039/501100002347
                Award ID: 01IS18036A
                Award ID: 01IS18053A
                Funded by: Chan Zuckerberg Initiative 10.13039/100014989
                Award ID: 182835
                Funded by: Austrian Science Fund 10.13039/501100002428
                Award ID: I3403-N32
                Award ID: P 30148
                Funded by: Joachim Herz Stiftung 10.13039/100008662
                Categories
                Public Health
                Methods

                group testing,sars-cov-2,pooling,covid-19,informative testing,rt-pcr

                Comments

                Comment on this article